A Phase 4 interventional study of Vevye® and Xiidra® in Dry Eye Disease, sponsored by Hoffmann-La Roche. Completed at 8 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-27.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing cyclosporine in Dry Eye Syndromes — 5 open to participants now, 5 under way, none of them phase 3. Cyclosporine · Dry Eye Syndromes.
Among the 45 studies testing cyclosporine in Dry Eye Syndromes, this one is the 2nd largest by enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2025, is one of 23 in phase 4, and was the 40th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.
Browse Dry Eye Syndromes studies →5 of the 45 studies testing cyclosporine in Dry Eye Syndromes are open now, in 2 countries. Recruiting first, the newest first:
Ocular Aesthetics, LLC dba Ocular Clinical Trials · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 18+
The University of New South Wales · Sites in Australia
Ages 18+
Canyon City Eyecare · Sites in United States
Ages 18+
Baylor College of Medicine
Ages 18+
By country, each count listing its studies:
Cyclosporine: first FDA approval 1983 (SANDIMMUNE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 378 is above the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 51 across the 41 interventional studies. Of the 35 that completed or were terminated, 11 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 45 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 1 study filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
5 of the studies testing cyclosporine in Dry Eye Syndromes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06898853The University of New South WalesThe Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes | 2026-12-30 |
| NCT07553455Canyon City EyecareVevye + Flarex Combination Therapy for Dry Eye | 2026-12-31 |
| NCT07224529University of Alabama at BirminghamEfficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction | 2027-02-01 |
| NCT07904728Ocular Aesthetics, LLC dba Ocular Clinical TrialsTreating Contact Lens Discomfort With Cyclosporine 0.1% Ophthalmic Solution | 2027-03-15 |
| NCT07368595Baylor College of MedicineComparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks | 2027-03-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 45 studies testing cyclosporine in Dry Eye Syndromes, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the performance of biomarkers and their responsiveness to standard-of-care treatments (Vevye® or Xiidra®), in participants with dry eye disease (DED) compared to healthy volunteers (control participants).
This study aims to characterize longitudinal changes in signs, symptoms, molecular, and imaging markers of the ocular surface to investigate pathological mechanisms and biomarkers (BMs) of DED after treatment with either of two commercially approved therapeutics (Vevye® [cyclosporine ophthalmic solution], Xiidra® [liftegrast ophthalmic solution]).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A. Inclusion Criteria for Participants with DED:
B. Inclusion Criteria for Healthy Volunteers:
- The participant does not have overt clinical signs of DED in either eye
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with evaporative dry eye (EDE), aqueous deficient dry eye (ADDE) and mixed dry eye will receive Vevye®, 1 milligrams per milliliter (mg/mL) as one drop into the affected eye(s), twice daily (BID) via topical ocular instillation for 12 weeks.
Drug: Vevye®
Participants with EDE, ADDE, and mixed dry eye will receive Xiidra®, 50 mg/mL as one drop into the affected eye(s), BID via topical ocular instillation for 12 weeks.
Drug: Xiidra®
Healthy volunteers will be enrolled as a control group and will not receive any treatment.
Participants will receive Vevye® (0.1% cyclosporine ophthalmic solution) as per the schedule described in the treatment arm.
Also known as: Cyclosporine Ophthalmic Solution
Participants will receive Xiidra® (5% lifitegrast ophthalmic solution) as per the schedule described in the treatment arm.
Also known as: Lifitegrast Ophthalmic Solution
Change From Baseline in Corneal Staining as Measured by Sodium Fluorescein
Time frame: Up to Week 12
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
No publications or documents are linked to this record.
Ran from Jul 2025 to primary completion in Jul 2026, 12 months.
Of 28 industry-sponsored phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 15. This study's 12 months is above that.
Counting every sponsor, half of 112 studies reached it within 12 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cyclosporine · Lifitegrast